NR1H4 and metabolic dysfunction-associated steatohepatitis: The non-BA tropifexor is another highly potent FXR agonist tested in the FLIGHT FXR phase 2 clinical trial (NCT02855164) in MASH patients with stage 1–3 fibrosis.